These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17092972)

  • 1. Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling?
    Buchert R; Thiele F; Thomasius R; Wilke F; Petersen K; Brenner W; Mester J; Spies L; Clausen M
    J Psychopharmacol; 2007 Aug; 21(6):628-34. PubMed ID: 17092972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET.
    Buchert R; Thomasius R; Nebeling B; Petersen K; Obrocki J; Jenicke L; Wilke F; Wartberg L; Zapletalova P; Clausen M
    J Nucl Med; 2003 Mar; 44(3):375-84. PubMed ID: 12621003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.
    Buchert R; Thomasius R; Wilke F; Petersen K; Nebeling B; Obrocki J; Schulze O; Schmidt U; Clausen M
    Am J Psychiatry; 2004 Jul; 161(7):1181-9. PubMed ID: 15229049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.
    McCann UD; Szabo Z; Seckin E; Rosenblatt P; Mathews WB; Ravert HT; Dannals RF; Ricaurte GA
    Neuropsychopharmacology; 2005 Sep; 30(9):1741-50. PubMed ID: 15841106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.
    Buchert R; Thomasius R; Petersen K; Wilke F; Obrocki J; Nebeling B; Wartberg L; Zapletalova P; Clausen M
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):188-99. PubMed ID: 16133393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.
    Kish SJ; Lerch J; Furukawa Y; Tong J; McCluskey T; Wilkins D; Houle S; Meyer J; Mundo E; Wilson AA; Rusjan PM; Saint-Cyr JA; Guttman M; Collins DL; Shapiro C; Warsh JJ; Boileau I
    Brain; 2010 Jun; 133(Pt 6):1779-97. PubMed ID: 20483717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults?
    Buchert R; Schulze O; Wilke F; Berding G; Thomasius R; Petersen K; Brenner W; Clausen M
    J Nucl Med; 2006 Jan; 47(1):38-42. PubMed ID: 16391185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
    Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
    Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM).
    Huang Y; Hwang DR; Bae SA; Sudo Y; Guo N; Zhu Z; Narendran R; Laruelle M
    Nucl Med Biol; 2004 Jul; 31(5):543-56. PubMed ID: 15219271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.
    Zhu Z; Guo N; Narendran R; Erritzoe D; Ekelund J; Hwang DR; Bae SA; Laruelle M; Huang Y
    Nucl Med Biol; 2004 Nov; 31(8):983-94. PubMed ID: 15607480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA).
    Huang Y; Narendran R; Bae SA; Erritzoe D; Guo N; Zhu Z; Hwang DR; Laruelle M
    Nucl Med Biol; 2004 Aug; 31(6):727-38. PubMed ID: 15246363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.
    Buchert R; Obrocki J; Thomasius R; Väterlein O; Petersen K; Jenicke L; Bohuslavizki KH; Clausen M
    Nucl Med Commun; 2001 Aug; 22(8):889-97. PubMed ID: 11473208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.
    Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM
    Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.
    Szabo Z; McCann UD; Wilson AA; Scheffel U; Owonikoko T; Mathews WB; Ravert HT; Hilton J; Dannals RF; Ricaurte GA
    J Nucl Med; 2002 May; 43(5):678-92. PubMed ID: 11994534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys.
    Kakiuchi T; Tsukada H; Fukumoto D; Nishiyama S
    Synapse; 2001 Jun; 40(3):170-9. PubMed ID: 11304754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.
    Vegting Y; Reneman L; Booij J
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3473-501. PubMed ID: 27568200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB.
    Frankle WG; Narendran R; Huang Y; Hwang DR; Lombardo I; Cangiano C; Gil R; Laruelle M; Abi-Dargham A
    Biol Psychiatry; 2005 Jun; 57(12):1510-6. PubMed ID: 15953487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method.
    Kim JS; Ichise M; Sangare J; Innis RB
    J Nucl Med; 2006 Feb; 47(2):208-14. PubMed ID: 16455625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans.
    Frankle WG; Huang Y; Hwang DR; Talbot PS; Slifstein M; Van Heertum R; Abi-Dargham A; Laruelle M
    J Nucl Med; 2004 Apr; 45(4):682-94. PubMed ID: 15073266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.